Geneseeq Publishes Promising Early Lung Cancer Detection Results in AJRCCM (Geneseeq Press Release)
P=NA | N=782 | "Geneseeq Technology Inc...announced high-performing results from a lung cancer study testing the company's early cancer detection model through program DECIPHER (Detecting Early Cancer by Inspecting ctDNA Features)....The model showed a high area under the curve (AUC) of 0.984, 0.987, and 0.974 for differentiating lung cancer patients from healthy individuals in the three validation cohorts. The model's robustness, repeatability and reproducibility were also tested, yielding great performance results. Most notably, the model can identify both squamous cell carcinoma and adenocarcinoma with a 93.3% and 87.0% sensitivity, at a 95.0% specificity. 'It is also sensitive to early pathological features, with a sensitivity of 83.2% at 95.0% specificity for stage I lung cancer, and a sensitivity of 85.0% for tumors less than 10mm'."